| Name | Title | Contact Details |
|---|
Carl Zeiss Meditec is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PreViser Corporation is a Mount Vernon, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Noesis Health is a Lynn Haven, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With iCAD`s technology, cancer has finally met its match. As a global medical technology leader providing innovative cancer detection and therapy solutions, our technologies empower clinicians worldwide with an arsenal of tools to detect cancer and stop it in its tracks – streamlining workflow, improving accuracy, and personalizing results like never before. The ProFound AI Breast Health Suite is the first, best, and only complete, triple-threat solution that combines cancer detection, density assessment, and risk evaluation – all designed to accelerate discovery and improve outcomes. Our leading-edge cancer detection solution, ProFound AI®, is clinically proven to find cancers earlier and with greater accuracy, while slashing reading time for radiologists by more than half. PowerLook® Density Assessment simplifies and standardizes breast density reporting and stratification, offering consistent, accurate and reliable breast density categorization. And the latest addition to our Breast AI Suite, ProFound AI® Risk, is the world`s first clinical decision support tool that provides an accurate short-term breast cancer risk estimation that is truly personalized for each woman, based only on her mammogram. Our Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is transforming the cancer treatment experience by empowering physicians to precisely and effectively target tumors anywhere in the body, anywhere in the world. Using the world`s smallest X-ray source, clinicians can precisely destroy disease while preserving healthy tissue, leaving cancer nowhere to hide.
Claret Medical has been the leader in the field of cerebral protection since 2011, with approximately 97% market share in Europe, and is the first in the category to be commercially available in the U.S.